查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1415363

心臟 POC 测试市场：按产品类型、生物标记类型和最终用户 - 2024-2030 年全球预测

Cardiac Point of Care Testing Market by Product (Analyzers, Kits & Assays, Software & Services), Biomarker Type (Cardiac Troponins, CK-MB Fraction, D-Dimer), End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年心臟POC检测市场规模为83.1亿美元，预计2024年将达到93.8亿美元，2030年将达到197.4亿美元，复合年增长率为13.14%。

心臟 POC 测试的全球市场

主要市场统计
基准年[2023] 83.1亿美元
预测年份 [2024] 93.8亿美元
预测年份 [2030] 197.4亿美元
复合年增长率（%） 13.14%
心臟POC测试市场-IMG1

心臟 POC 测试是指对心臟病患者进行床边或患者附近测试，有助于即时做出临床决策。这种形式的诊断测试是在传统实验室环境之外进行的，通常在患者护理时间和地点进行，例如急诊室、诊所、救护车服务和重症监护病房。心臟 POC 测试的主要目的是获得快速测试结果，可用于评估患者的心臟状态，以便及时、知情的治疗性介入。它通常用于检测与心臟事件相关的生物标记物，例如肌红蛋白、同型半胱氨酸和 Hs C 反应蛋白 (CRP)。在快速发展的医疗保健领域，由于对快速、准确的心血管诊断的需求不断增长，心臟护理点 (POC) 测试市场正在蓬勃发展。该市场的定义是设计、製造和销售易于使用的诊断设备和相应的反应剂，以促进现场心血管健康评估。这些设备可用于急诊环境，为包括医院、门诊诊所和家庭医疗保健在内的各种客户提供服务。心血管疾病在人群中的盛行率不断上升、技术进步有望提高诊断可靠性以及全球医疗保健投资的增加，推动了心臟 POC 测试的普及。然而，严格的法律规范、对诊断准确性的担忧以及新兴市场的财务限制等障碍正在阻碍全球心臟 POC 市场的扩张。心臟 POC 测试技术的改进和稳定发展，包括提高测试能力的设备和生物标誌物，为市场供应商描绘了充满希望的机会。

区域洞察

在美洲，由于心血管疾病的流行、医疗成本的上升以及强大的医疗基础设施的存在，心臟 POC 测试市场继续呈现强劲增长。此外，最尖端科技的采用、积极的政府倡议以及由于主要市场参与者的存在而提供的广泛产品正在推动成长。 EMEA（欧洲、中东和非洲）地区的市场形势充满活力，欧洲市场受益于有利的政府政策、大量老年人口以及旨在减轻倡议疾病负担的倡议不断增多。由于中东国家医疗保健投资增加以及非洲心臟健康意识不断增强，中东和非洲市场不断增长。亚太地区是心臟 POC 检测前景看好的市场，与美洲和欧洲、中东和非洲相比，预计成长率最高。这是由中国和印度等国家庞大的人口基数、快速发展的医疗基础设施以及不断增长的医疗支出所推动的。此外，包括心臟病文明病在该地区呈上升趋势，进一步增加了对快速有效诊断方法的需求。

FPNV定位矩阵

FPNV定位矩阵对于评估心臟POC测试市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可对心臟 POC 测试市场供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵考察，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

该报告对以下几个方面提供了宝贵的见解：

1-市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2-市场开拓：我们深入研究利润丰厚的新兴市场，并分析它们在成熟细分市场中的渗透率。

3- 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4-竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5- 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1-心臟POC检测市场的市场规模和预测是多少？

2-在心臟 POC 测试市场的预测期内，有哪些产品、细分市场、应用和领域需要考虑投资？

3-心臟POC检测市场的技术趋势和法律规范是什么？

4-心臟POC测试市场主要供应商的市场占有率是多少？

5-进入心臟POC检测市场合适的型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 人群心血管疾病发生率增加
      • 政府对引入 POC 测试的有利倡议
      • 改善世界各地经济体的医疗保健支出
    • 抑制因素
      • 心臟 POC 测试中使用的材料和组件的成本变化
    • 机会
      • 心臟 POC 测试的改进和持续进步
      • 新生物标记物的开发正在取得进展，以提高检测能力
    • 任务
      • 心臟 POC 测试的操作和技术复杂性
  • 市场区隔分析
    • 产品：诊所对多重检测的需求增加
    • 生物标记类型：用于早期心臟检测的心臟型脂肪酸结合蛋白质（H-FABP）和缺血修饰白蛋白（IMA）的需求不断增加
    • 最终用户：在具有大样本量的复杂系统的诊断实验室中增加使用心臟 POC 测试
  • 市场趋势分析
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范

第六章心臟 POC 测试市场：依产品

  • 分析仪
  • 套件和检测
  • 软体和服务

第七章按生物标记类型分類的心臟 POC 测试市场

  • 心肌肌钙蛋白
  • CK-MB分数
  • D-二聚体
  • 心型脂肪酸结合蛋白质（H-FABP）
  • 同型半胱氨酸
  • hs C 反应蛋白 (CRP)
  • 缺血修饰白蛋白 (IMA)
  • 肌红蛋白
  • 利尿钠胜肽(NP)
    • 心房钠尿胜肽(ANP)
    • B 型利尿钠胜肽(BNP)
    • N 端 BNP 前驱物 (NT-BNP 前驱物)
  • sCD40L

第 8 章 心臟 POC 测试市场：依最终用户分类

  • 诊断实验室
  • 医院和诊所
  • 研究和学术机构

第九章 北美和南美心臟POC测试市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太心臟POC测试市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲心臟POC测试市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争形势

  • FPNV定位矩阵
  • 市场占有率分析：主要企业
  • 主要企业竞争情境分析
    • 合约、合作和伙伴关係
    • 新产品发布和功能增强
    • 奖项/奖励/扩展

第13章竞争产品组合

  • 主要公司简介
    • Abaxis, Inc. by Zoetis Inc
    • Abbott Laboratories
    • ACON Laboratories, Inc.
    • Beckman Coulter
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • bioMerieux SA
    • Cardiac Insight Inc.
    • CardioGenics Holdings Inc.
    • Chembio Diagnostic Systems, Inc. by Biosynex
    • EKF Diagnostics
    • F. Hoffmann-La Roche Ltd.
    • Fujirebio
    • Horiba, Ltd.
    • I-Sens Inc.
    • LifeSign LLC
    • Nexus Dx, Inc. by Sinocare
    • Nova Biomedical
    • PTS Diagnostics by Danaher Corporation
    • Quidel Corporation
    • Radiometer Medical ApS
    • Randox Laboratories Ltd.
    • Siemens Healthineers AG
    • Thermo Fisher Scientific Inc.
    • Trividia Health, Inc.
  • 主要产品系列

第十四章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-3F5063247F54

[183 Pages Report] The Cardiac Point of Care Testing Market size was estimated at USD 8.31 billion in 2023 and expected to reach USD 9.38 billion in 2024, at a CAGR 13.14% to reach USD 19.74 billion by 2030.

Global Cardiac Point of Care Testing Market

KEY MARKET STATISTICS
Base Year [2023] USD 8.31 billion
Estimated Year [2024] USD 9.38 billion
Forecast Year [2030] USD 19.74 billion
CAGR (%) 13.14%
Cardiac Point of Care Testing Market - IMG1

Cardiac point of care testing refers to the bedside or near-patient testing of cardiac patients that facilitates immediate clinical decision-making. This form of diagnostic testing is performed outside of traditional laboratory environments, typically at the time and place of patient care, such as in emergency departments, clinics, ambulance services, or critical care units. The primary goal of cardiac point of care testing is to obtain rapid test results that can be used to assess the condition of a patient's heart, enabling timely and informed treatment interventions. It is often utilized for the detection of biomarkers associated with cardiac events, including myoglobin, homocysteine, and hs C-reactive protein (CRP). In the rapidly advancing domain of healthcare, the cardiac point of care (POC) testing market is gaining momentum, driven by the escalating need for swift and precise cardiovascular diagnostics. This market is defined by the engineering, manufacturing, and commerce of user-friendly diagnostic instruments and their corresponding reactive agents that facilitate on-site cardiovascular health assessments. These devices, instrumental within acute medical scenarios, cater to a diverse clientele across hospitals, outpatient clinics, and home healthcare. The proliferation of cardiac point of care testing is driven by increasing incidences of cardiovascular diseases among the population, technological strides that promise enhanced diagnostic veracity, and rising global healthcare investment. Despite obstacles such as stringent regulatory frameworks, concerns over diagnostic accuracy, and financial limitations in developing health ecosystems hinder the scope of the global cardiac point of care market. Improvements and robust advancements in cardiac POC testing technologies, including devices and biomarkers to improve testing capabilities, portray promising opportunities for the market vendors.

Regional Insights

In the Americas, the market for cardiac point of care testing continues to display robust growth, driven by the prevalence of cardiovascular diseases, rising healthcare expenditure, and the presence of robust healthcare infrastructure. Additionally, the growth is facilitated by the adoption of cutting-edge technologies, active government initiatives, and the availability of a wide range of products owing to the presence of significant market players. The EMEA region experiences a dynamic market landscape for cardiac point of care testing, where the European market benefits from favorable government policies, a high geriatric population, and an increasing number of initiatives aimed at lowering the burden of cardiovascular diseases. The Middle East and Africa showcase a growing market due to rising healthcare investments in the Middle Eastern countries and the growing awareness of cardiac health in Africa. The APAC region represents a promising market for cardiac point of care testing, with expectations for the highest growth rate in comparison to the Americas and EMEA. This is attributed to the vast population base, rapidly developing healthcare infrastructure in countries including China and India, and an increase in healthcare spending. Additionally, the region is experiencing a rise in lifestyle-related diseases, including heart conditions, which further propels the demand for quick and efficient diagnostic methods.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cardiac Point of Care Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cardiac Point of Care Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cardiac Point of Care Testing Market, highlighting leading vendors and their innovative profiles. These include Abaxis, Inc. by Zoetis Inc, Abbott Laboratories, ACON Laboratories, Inc., Beckman Coulter, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Cardiac Insight Inc., CardioGenics Holdings Inc., Chembio Diagnostic Systems, Inc. by Biosynex, EKF Diagnostics, F. Hoffmann-La Roche Ltd., Fujirebio, Horiba, Ltd., I-Sens Inc., LifeSign LLC, Nexus Dx, Inc. by Sinocare, Nova Biomedical, PTS Diagnostics by Danaher Corporation, Quidel Corporation, Radiometer Medical ApS, Randox Laboratories Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Trividia Health, Inc..

Market Segmentation & Coverage

This research report categorizes the Cardiac Point of Care Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Analyzers
    • Kits & Assays
    • Software & Services
  • Biomarker Type
    • Cardiac Troponins
    • CK-MB Fraction
    • D-Dimer
    • Heart-Type Fatty Acid-Binding Protein (H-FABP)
    • Homocysteine
    • hs C-reactive Protein (CRP)
    • Ischemia-Modified Albumin (IMA)
    • Myoglobin
    • Natriuretic Peptides (NPs) Atrial Natriuretic Peptide (ANP)
      • B-type Natriuretic Peptide (BNP)
      • N-terminal proBNP (NT-proBNP)
    • sCD40L
  • End-User
    • Diagnostic Laboratories
    • Hospitals & Clinics
    • Research & Academic Institutes
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cardiac Point of Care Testing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cardiac Point of Care Testing Market?

3. What are the technology trends and regulatory frameworks in the Cardiac Point of Care Testing Market?

4. What is the market share of the leading vendors in the Cardiac Point of Care Testing Market?

5. Which modes and strategic moves are suitable for entering the Cardiac Point of Care Testing Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Cardiac Point of Care Testing Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidences of cardiovascular disorders among the population
      • 5.1.1.2. Favorable government initiatives for the introduction of POC testing
      • 5.1.1.3. Improving healthcare expenditure across economies worldwide
    • 5.1.2. Restraints
      • 5.1.2.1. Fluctuating cost of materials and components used in cardiac POC testing
    • 5.1.3. Opportunities
      • 5.1.3.1. Improvements and continuous advancements in cardiac POC testing
      • 5.1.3.2. Advances in the development of new biomarkers to improve testing capabilities
    • 5.1.4. Challenges
      • 5.1.4.1. Operational and technical complexities in cardiac POC testing
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Increasing demand for multiplex assays across clinics
    • 5.2.2. Biomarker Type: Increasing demand for heart-type fatty acid-binding protein (H-FABP) and ischemia-modified albumin (IMA) for early cardiac detection
    • 5.2.3. End-user: Rising usage of cardiac POC testing in diagnostic laboratories for complex systems with high sample capacities
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Cardiac Point of Care Testing Market, by Product

  • 6.1. Introduction
  • 6.2. Analyzers
  • 6.3. Kits & Assays
  • 6.4. Software & Services

7. Cardiac Point of Care Testing Market, by Biomarker Type

  • 7.1. Introduction
  • 7.2. Cardiac Troponins
  • 7.3. CK-MB Fraction
  • 7.4. D-Dimer
  • 7.5. Heart-Type Fatty Acid-Binding Protein (H-FABP)
  • 7.6. Homocysteine
  • 7.7. hs C-reactive Protein (CRP)
  • 7.8. Ischemia-Modified Albumin (IMA)
  • 7.9. Myoglobin
  • 7.10. Natriuretic Peptides (NPs)
    • 7.11.1. Atrial Natriuretic Peptide (ANP)
    • 7.11.2. B-type Natriuretic Peptide (BNP)
    • 7.11.3. N-terminal proBNP (NT-proBNP)
  • 7.11. sCD40L

8. Cardiac Point of Care Testing Market, by End-User

  • 8.1. Introduction
  • 8.2. Diagnostic Laboratories
  • 8.3. Hospitals & Clinics
  • 8.4. Research & Academic Institutes

9. Americas Cardiac Point of Care Testing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cardiac Point of Care Testing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cardiac Point of Care Testing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player
    • 12.3.1. Agreement, Collaboration, & Partnership
      • 12.3.1.1. Jana Care to Enter Collaboration with Roche to Develop and Distribute Blood Testing Platform to Improve Remote Care for Patients With Chronic Kidney and Heart Disease
    • 12.3.2. New Product Launch & Enhancement
      • 12.3.2.1. Cipla expands diagnostics portfolio, launches point-of-care testing device
    • 12.3.3. Award, Recognition, & Expansion
      • 12.3.3.1. Hipro Point-of-Care Diagnostics Launched in India

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Abaxis, Inc. by Zoetis Inc
    • 13.1.2. Abbott Laboratories
    • 13.1.3. ACON Laboratories, Inc.
    • 13.1.4. Beckman Coulter
    • 13.1.5. Becton, Dickinson and Company
    • 13.1.6. Bio-Rad Laboratories, Inc.
    • 13.1.7. bioMerieux SA
    • 13.1.8. Cardiac Insight Inc.
    • 13.1.9. CardioGenics Holdings Inc.
    • 13.1.10. Chembio Diagnostic Systems, Inc. by Biosynex
    • 13.1.11. EKF Diagnostics
    • 13.1.12. F. Hoffmann-La Roche Ltd.
    • 13.1.13. Fujirebio
    • 13.1.14. Horiba, Ltd.
    • 13.1.15. I-Sens Inc.
    • 13.1.16. LifeSign LLC
    • 13.1.17. Nexus Dx, Inc. by Sinocare
    • 13.1.18. Nova Biomedical
    • 13.1.19. PTS Diagnostics by Danaher Corporation
    • 13.1.20. Quidel Corporation
    • 13.1.21. Radiometer Medical ApS
    • 13.1.22. Randox Laboratories Ltd.
    • 13.1.23. Siemens Healthineers AG
    • 13.1.24. Thermo Fisher Scientific Inc.
    • 13.1.25. Trividia Health, Inc.
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. CARDIAC POINT OF CARE TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. CARDIAC POINT OF CARE TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. CARDIAC POINT OF CARE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CARDIAC POINT OF CARE TESTING MARKET DYNAMICS
  • FIGURE 7. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2030 (%)
  • FIGURE 10. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. CARDIAC POINT OF CARE TESTING MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. CARDIAC POINT OF CARE TESTING MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. CARDIAC POINT OF CARE TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. CARDIAC POINT OF CARE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 6. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY KITS & ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 10. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CARDIAC TROPONINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CK-MB FRACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY D-DIMER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HEART-TYPE FATTY ACID-BINDING PROTEIN (H-FABP), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOMOCYSTEINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HS C-REACTIVE PROTEIN (CRP), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ISCHEMIA-MODIFIED ALBUMIN (IMA), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY MYOGLOBIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 20. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ATRIAL NATRIURETIC PEPTIDE (ANP), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY B-TYPE NATRIURETIC PEPTIDE (BNP), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY N-TERMINAL PROBNP (NT-PROBNP), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY SCD40L, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 44. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 66. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 70. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 139. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 155. POLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 159. QATAR CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 196. CARDIAC POINT OF CARE TESTING MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 197. CARDIAC POINT OF CARE TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 198. CARDIAC POINT OF CARE TESTING MARKET LICENSE & PRICING